A clinical trial investigator suggested that the low effectiveness of the German pharmaceutical company CureVac’s COVID-19 vaccine was due to inadequate dosage.
The CureVac vaccine showed an efficacy of 47% in the interim results of the phase 3 clinical trial, and obtained results that fell short of the domestic and international preventive efficacy standards.
This is significantly lower than the prevention effect of more than 90% of Pfizer and Moderna vaccines made with the same mRNA vaccine platform.
While some experts are skeptical that the final clinical results will be only as effective as the intermediate results, the German University Hospital of Tübingen, which conducted this clinical trial, announced on the 17th that the low effectiveness “may be due to the dosage”.
Unlike Pfizer and Moderna, CureVac administered the vaccine without modifying mRNA, and it was explained that a small dose was administered to clinical participants in consideration of possible side effects.
The Pfizer vaccine contains 30 micrograms per dose and the Moderna vaccine contains 100 micrograms of mRNA, while the CureVac vaccine contains only 12 micrograms of mRNA.
CureVac said that it made this choice in the sense that reducing the amount of mRNA makes it easier to store and advantageous in terms of price.
Earlier, CureVac announced the interim results of the clinical trial on the 16th and explained that the low effectiveness was due to ‘new Corona 19 variants’. However, in the case of Pfizer and Moderna vaccines, although the protective effect against the mutant was reduced, it was still sufficiently effective, which was insufficient to explain the low effectiveness of the CureVac vaccine.
It is noteworthy whether the improved efficacy can be confirmed in the final clinical results based on this new explanation, which seems to be due to the low dose.
By Moon Se-young, staff reporter [email protected]
Copyrightⓒ ‘Honest knowledge for health’ Comedy.com (http://kormedi.com) / Unauthorized reproduction-redistribution prohibited
Source: 코메디닷컴 by kormedi.com.
*The article has been translated based on the content of 코메디닷컴 by kormedi.com. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!
*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.
*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!